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Abstract
Background
Scabies is endemic in many Aboriginal and Torres Strait Islander communities, with 69% of
infants infected in the first year of life. We report the outcomes against scabies of two oral
ivermectin mass drug administrations (MDAs) delivered 12 months apart in a remote Aus-
tralian Aboriginal community.
Methods
Utilizing a before and after study design, we measured scabies prevalence through popula-
tion census with sequential MDAs at baseline and month 12. Surveys at months 6 and 18
determined disease acquisition and treatment failures. Scabies infestations were diagnosed
clinically with additional laboratory investigations for crusted scabies. Non-pregnant partici-
pants weighing15 kg were administered a single 200 μg/kg ivermectin dose, repeated
after 2–3 weeks if scabies was diagnosed, others followed a standard alternative algorithm.
Principal Findings
We saw >1000 participants at each population census. Scabies prevalence fell from 4% at
baseline to 1% at month 6. Prevalence rose to 9% at month 12 amongst the baseline cohort
in association with an identified exposure to a presumptive crusted scabies case with a
higher prevalence of 14% amongst new entries to the cohort. At month 18, scabies preva-
lence fell to 2%. Scabies acquisitions six months after each MDA were 1% and 2% whilst
treatment failures were 6% and 5% respectively.
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Conclusion
Scabies prevalence reduced in the six months after each MDA with a low risk of acquisition
(1–2%). However, in a setting where living conditions are conducive to high scabies trans-
missibility, exposure to presumptive crusted scabies and population mobility, a sustained
reduction in prevalence was not achieved.
Clinical Trial Registration
Australian New Zealand Clinical Trial Register (ACTRN—12609000654257).
Author Summary
Scabies is endemic in many Australian Aboriginal and Torres Strait Islander communities,
with 69% of infants infected in the first year of life. Previous mass drug administration
(MDA) programs using topical acaricides to decrease scabies prevalence have had varying
degrees of success in Australia. We were invited by one community in eastern Arnhem
Land to develop and deliver an oral-ivermectin MDA. Utilizing a before and after study
design, we measured scabies prevalence through population census with sequential MDAs
at baseline and month 12. Scabies prevalence fell from 4% at baseline to 1% at month 6,
rising to 9% at month 12 in association with an identified exposure to a presumptive
crusted scabies case. For new entries to the cohort at month 12 scabies prevalence was
higher at 14%. We were able to demonstrate a reduction in scabies prevalence in the six
months after each MDA with a low risk of acquisition (1–2%); however, a sustained reduc-
tion was not achieved.
Introduction
Scabies mites infect up to 300 million people worldwide, most of whom are children living in
poverty and overcrowded conditions.[1–3] In remote Australian Aboriginal communities, sca-
bies has been near universal during the first year of life (69%).[4] Secondary infections with
highly pathogenic bacterial pathogens Streptococcus pyogenes and Staphylococcus aureus con-
tribute to high rates of pyoderma in these communities.[5–8] Acute post-streptococcal glomer-
ulonephritis (APSGN) and streptococcal and staphylococcal sepsis,[9],[10] are recognised
complications of pyoderma, whereas rheumatic fever, rheumatic heart disease and chronic
renal failure are postulated sequelae that all occur in Australian Aboriginal people at the high-
est rates in the world.[11,12] In contrast, scabies is infrequently seen in non-Indigenous Aus-
tralians.[2,8,13]
Individuals with scabies classically present with profuse pruritus involving only 5–15 mites
per person, whereas an individual with crusted scabies, a rare condition, can have thousands of
mites.[14,15] Well documented to occur in immune compromised hosts, most Aboriginal peo-
ple identified with crusted scabies have no definable immune defect.[16] People with crusted
scabies are highly infectious and have been identified as core transmitters in scabies epidemic
cycles and institutional outbreaks.[3,16,17] Prior to 1996 and the introduction of ivermectin in
Northern Territory (NT) Australia, there was a 5-year mortality rate of up to 50% for people
with crusted scabies.[16]
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Mass drug administration (MDA) programs using topical acaricides to decrease scabies
prevalence have had varying degrees of success in Australia.[5,8,13] Due to high endemicity,
high transmissibility of infestations, low treatment uptake and limited regional coverage, the
presence of crusted scabies in communities and mobility of regional populations, a sustained
reduction in prevalence has not been achieved to date in remote Aboriginal communities.
[1,8,18] Having an established collaboration through the East Arnhem Healthy Skin Program
[1,19,20] which demonstrated poor uptake of topical acaricides in household contacts,[1] we
were invited by one community in eastern Arnhem Land to develop a proposal for an oral-iver-
mectin MDA targeting both scabies and strongyloidiasis. Strongyloidiasis is an infection with
the intestinal nematode parasite, Strongyloides stercoralis, for which ivermectin is the first-line
treatment.[21] Here we report the outcomes against scabies of the MDA program designed in
collaboration with the participating community.
Methods
The setting was a remote island community, 550km from Darwin, Australia with an estimated
population of 2121.[22] Most residents lived in the main community; 200–400 lived in one of
10 associated homelands outside the community (five of which were accessible only by air/
water).
In consultation with the community, we designed a staged roll-out of two MDAs, imple-
mented 12 months apart for the respective households/homelands. MDAs are typically
designed to be implemented within a short time frame to maximise reduction of infective
stages. However, our consultations with the community stressed the need for a more extended
roll-out period to encompass house to house consultation, screening and treatment involving
locally trained workers. There were 159 houses in the main community at the start of the proj-
ect and 165 houses at the second MDA. The program was evaluated in a before and after study
design.
We conducted population censuses in 2010 (baseline) and 2011 (month 12) to screen for
scabies and strongyloidiasis that all residents were eligible to participate in. The MDA was
delivered at the same time using an allocated drug regimen (Table 1). Two surveys were con-
ducted six months after each MDA (month 6 and 18) to: a) follow-up participants who were
positive for scabies and/or had an equivocal/positive Strongyloides result in the census six
months prior, b) screen a computer-generated random sample of participants who were nega-
tive for both scabies and strongyloidiasis in the census six months prior and c) follow-up con-
tacts of scabies acquisitions diagnosed at month 6 or 18. Given the staged program roll-out,
Table 1. Drug regimen for MDAs and treatment of scabies.
Group Medications administered at baseline & month
12
Treatment after 10–42 days for
those diagnosed with scabies
Weight Day 1–3 Day 10–42
<3.5 kg Topical 10% crotamiton daily for 3 consecutive
days
Topical 10% crotamiton daily for
3 consecutive days
3.5 kg<6 kg Topical 5% permethrin Topical 5% permethrin
6 kg <15 kg Topical 5% permethrin & oral albendazole 200
mg (6–10 kg) or 400 mg (10-<15 kg) daily for 3
consecutive days
Topical 5% permethrin
Not pregnant and
weight 15 kg
Oral ivermectin 200 μg/kg Oral ivermectin 200 μg/kg
Pregnant Topical 5% permethrin Topical 5% permethrin
doi:10.1371/journal.pntd.0004151.t001
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subsequent visits to households were scheduled to accommodate the planned 6–12 month fol-
low-up timeline as per the study protocol [23].
An allocated drug regimen for both scabies and strongyloidiasis was delivered based on
weight and pregnancy status (Table 1). All non-pregnant participants who weighed15 kg
were administered a single dose of ivermectin 200 μg/kg at baseline and at month 12. Those
ineligible for ivermectin received either topical 5% permethrin or 10% crotamiton. Treatment
was repeated after 2–3 weeks if scabies and/or strongyloidiasis were diagnosed. All household
contacts of participants diagnosed with scabies were either treated as part of the MDA or
referred to the clinic. At the month 6 and 18 surveys, those diagnosed with scabies and their
household contacts were provided with treatment and follow-up. Strongyloidiasis cases were
treated but not their family contacts.
Residents were excluded from the MDA if they had an allergy to any components of the
allocated drug regimen or had received the eligible study medication in the previous seven
days. All female study participants aged 12–45 years had the option of a urinary test to deter-
mine pregnancy status as ivermectin safety in pregnancy has not been established.[24] Those
not tested were allocated to the same treatment regimen as pregnant women. Pregnancy testing
and medication administration was undertaken in portable work stations ensuring individual
privacy. Adherence with the allocated drug regimen was monitored by direct observation of
oral therapy and through verbal discussions with those applying topical acaricides.
Scabies was diagnosed clinically from observation of exposed skin. We classified scabies as:
scabies-like lesions in a person who had either an itch, lesions in a typical location, or a house-
hold member with an itch. We accepted typical scabies lesions as being burrows, erythematous
papules and macules, scales, vesicles, bullae, crusts, pustules, nodules and/or excoriations
located in the finger web spaces, flexor surfaces of the wrists and elbows, axillae, head, feet,
palms or buttocks in children or male genitalia and female breasts where assessed. Flipcharts
[25] were used by Aboriginal Health Practitioners, Registered Nurses and ACWs to assist with
the diagnosis of scabies and pyoderma. Participants who had a clinical diagnosis of suspected
crusted scabies were referred to the local health service for laboratory confirmation and medi-
cal care according to locally developed guidelines which have been adopted internationally.[26]
Data were analysed using Stata 13 (StataCorp LP). Scabies prevalence at baseline and month
12 was calculated as a proportion of those seen who were diagnosed with scabies. At month 6
and 18 surveys, prevalence was determined as a weighted average of (i) treatment failure rate—
the prevalence for participants seen with scabies at the survey who had scabies at the popula-
tion census six months prior, and (ii) acquisition rate—the prevalence for participants seen at
the survey who did not have scabies at the census six months prior. In determination of scabies
acquisition, we also included those who were Strongyloides positive/equivocal but scabies nega-
tive in the denominator along with the computer generated randomly selected negatives from
six months prior, as there was no relation between scabies and strongyloidiasis at baseline or
month 12. Pyoderma prevalence was reported at baseline and month 12. Per protocol treat-
ment was calculated as a proportion of those eligible for the drug regimen who were adminis-
tered medication as outlined in Table 1.
Data entry was validated by double entering 15% of the records. The data entry error rate
for variables used in the analysis was<5%. Data is available from the Dryad Digital Reposi-
tory. [27]
Project Registration and Ethics Statement
The project was registered with the Australian New Zealand Clinical Trial Register (ACTRN—
12609000654257)[23] and received ethical approval from Human Research Ethics Committee
Impact of Ivermectin MDA on Scabies Prevalence
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004151 October 30, 2015 4 / 13
of the Northern Territory Department of Health and Menzies School of Health Research
(EC00153—project 09/34).
Study recruitment was conducted by Aboriginal Community Workers (ACWs) who had
completed a nationally accredited training program (Certificate II in Child Health Research
70131NT). The ACWs visited each house to discuss the project with family members and
establish a household occupancy list. Ascertainment of written informed consent was obtained
using a pictorial flipchart that incorporated a culturally-appropriate process to explain the
project.[28] Parents or registered caregivers provided written consent for children aged<18
years and additional written assent was obtained from children aged 12-<18 years.
Results
At baseline, there were 1256 residents on the household occupancy lists in the population cen-
sus (March-September 2010), of which 1013 (81%) consented to participate. Most participants
(n = 960, 95%) were seen over a four month period (April-July). The median number of partic-
ipants per house was nine (IQR 4–13) from 127 (80%) houses visited. Non-participating house-
holds were mostly those occupied by non-Aboriginal residents working in the community.
Seven of the 10 homelands consented to participate; one refused whilst residents from the
other two homelands were seen in houses in the main community. A total of 1002 participants
had data recorded on scabies at baseline, with scabies data missing for the remaining 11 partici-
pants (1%).
At month 12, there were 1163 residents on the household occupancy lists in the second pop-
ulation census (April-October 2011), of whom 1060 (91%) participated (~150 per month).
There were 700 (66%) whom had also been seen at baseline and 360 (34%) new participants
not previously seen. The median number of participants per house was 8 (IQR 3–12) from 133
(81%) houses visited. The median time per person between the baseline and month 12 census
was 14 months (IQR 12–17 months). Most participants (96%) received the per protocol MDA
regimen at baseline and 12, whilst 72% of those diagnosed with scabies received their second
treatment as per protocol. No adverse events following administration of medications were
reported.
Scabies Prevalence
Scabies prevalence among the baseline cohort was 4% and remained relatively stable during the
initial assessment period (2%, 6%, 3% and 5% per month from April-July 2010 respectively
when 91% of the baseline cohort were seen). At the month 6 survey, prevalence was 1% but
increased to 9% at month 12 (5% absolute increase from baseline to month 12 for the baseline
cohort) (Fig 1). At month 18, prevalence fell to 2%. The median age of participants with scabies
was 11 years (IQR 6–38 years) with more females at baseline diagnosed with scabies than
males (Table 2). Of the 42 participants diagnosed with scabies, 8/35 (23%) had infected scabies.
Prevalence among the baseline cohort had increased from 4% to 9% at month 12, whereas
prevalence among new entries to the cohort (those seen for the first time at month 12) was
14% (Fig 1). In addition to the new cohort entries, the increased prevalence at month 12 was
influenced by a cluster of cases epidemiologically linked to a participant diagnosed with pre-
sumptive crusted scabies. Prevalence within the baseline cohort of those who were known con-
tacts rose from 7% (7/96) at baseline to 18% (17/96) at month 12, whereas prevalence amongst
others who were not known contacts within the baseline cohort rose from 4% (23/598) at base-
line to 8% (46/604) at month 12. Of the 113 participants diagnosed with scabies, 34/105 (32%)
had infected scabies.
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The presumptive crusted scabies case was identified in May 2011, a school age participant
who had been receiving topical acaricide treatment from the school nurse every two weeks for
the previous two months. With support from nine public health personnel who joined the
study team, we identified 13 priority houses for follow-up, three of which were houses where
the presumptive crusted scabies participant had been living over the previous four weeks, and
10 other households that had school contacts with scabies.
There were 184 people identified as residing in these 13 houses of whom 141 (77%) were
seen; a median of 13 (IQR 10–18) participants per house (Fig 2). Of the 141 participants seen,
91 (65%) were from the baseline cohort of whom 16 (18%) had scabies at month 12. Of the 50
new participants seen for the first time in the priority houses, eight (16%) had scabies. Scabies
prevalence within these 13 households collectively was 17% (n = 24). Almost all (98%) of those
seen received ivermectin or 5% permethrin at the first visit.
Fig 1. Scabies prevalence at population censuses (2010 & 2011) andmonth 6 & 18 surveys.
doi:10.1371/journal.pntd.0004151.g001
Table 2. Participant details for the population census at month 0 and 12.
Yes scabies No scabies Total
Month 0 n = 42 n = 960 n = 1002
Median age (IQR) 11 (6–40) 21 (9–37) 21 (9–37)
Gender
Male 9 (21%) 484 (50%) 493 (49%)
Female 33 (79%) 476 (50%) 509 (51%)
Month 12 n = 113 n = 947 n = 1060
Median age (IQR) 11 (6–19) 22 (10–36) 21 (9–35)
Gender
Male 59 (52%) 478 (50%) 537 (51%)
Female 54 (48%) 469 (50%) 523 (49%)
doi:10.1371/journal.pntd.0004151.t002
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On follow-up, 77/184 residents (42%) from the 13 priority houses were seen again at visit 2,
median 37 days (IQR 23–42) after visit 1, with an acquisition rate of 4%. Of the 24 participants
observed with scabies lesions at visit 1, 18 (75%) were re-treated at visit 2 (12 had lesions pres-
ent when reviewed). Follow-up of these priority houses was completed within two months.
The increase in scabies prevalence at month 12 was most evident among children<15 years
of age and was highest amongst new entries to the cohort (Fig 3). Pyoderma prevalence where
the sores were described as purulent or crusted also increased amongst these age groups at
month 12 (Fig 4).
Month 6 and 18
Scabies treatment failures and acquisition were low throughout the study period (S1 and S2
Tables). The treatment failure rate was 6% (2/35) at month 6 and 5% (5/91) at month 18. The
Fig 2. Flowchart of visits to participants in 13 priority houses.
doi:10.1371/journal.pntd.0004151.g002
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Fig 3. Scabies prevalence at baseline &month 12, by age group.
doi:10.1371/journal.pntd.0004151.g003
Fig 4. Pyoderma prevalence at baseline &month 12, by age group.
doi:10.1371/journal.pntd.0004151.g004
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acquisition rate was 1% (4/352) at month 6 and 2% (6/276) at month 18. The median time
between participant visits from baseline to month 6 was six months (IQR 5–7 months) and
from month 12 to 18, eight months (IQR 7–10).
Discussion
In our study, MDA incorporating ivermectin had a demonstrable but relatively short-term
impact on scabies prevalence. In the six-months following each MDA, both the low overall
prevalence (1–3%) and the low acquisition rates (1–2%) suggest that transmission was substan-
tially reduced. However, the rapid rise in prevalence at month 12 highlights that an MDA pro-
gram, where utilised, needs to be incorporated with a multi-faceted control program and
ongoing surveillance in the community.
MDAs have been used to control and eliminate diseases for more than 25 years.[29] Iver-
mectin is one of the most commonly used drugs worldwide in the treatment of strongyloidiasis,
lymphatic filariasis, and onchocerciasis.[30] It is increasingly being used to treat other parasitic
infections including scabies,[31] pediculosis capitis [32] and malaria.[33] In 2014, Merck
Sharp and Dhome updated the indications for ivermectin use to include treatment of crusted
scabies and classical scabies if topical treatment is ineffective.[24,34].
Scabies is a neglected tropical disease,[35] ubiquitous in Australian Aboriginal and Torres
Strait Islander communities, despite repeated MDAs with topical acaricides.[8],[3] Infestations
are highly transmissible,[3] and as this study shows, prevalence escalates in the presence of
high exposure (prevalence amongst known contacts of the presumptive crusted scabies case
rose from 7% at baseline to 18% at month 12) and a high proportion of mobility (36% new
entries to the cohort at month 12, of whom 14% had scabies). Others have shown the impact of
exposure to crusted scabies [36] and overcrowded living conditions [1] on scabies prevalence.
Outbreaks [37] and high scabies prevalence [38] have previously been linked with epidemics of
APSGN, the sequelae of a post streptococcal infection that is common in developing countries
and Indigenous populations.[10]
The participation rate among residents within the community was noteworthy (80–95%)
encompassing an informed consent process implemented with and by the community. Under
the guidance of elders and key community stakeholders, the development of a pictorial flip-
chart that incorporated a culturally-appropriate process to explain the project was fundamental
in obtaining informed consent.[28] The flipchart incorporated a local story well known in the
community which we had gained specific approval to use and translate into local language.
That some members declined participation is testament to the culturally appropriate processes
enabled within this study. Moreover, the process of ongoing engagement and the culturally
acceptable arrangements regarding pregnancy testing, screening and steady (as opposed to
rapid) roll-out of the program were integral to the reach achieved over the course of the study.
A previous attempt to implement an ivermectin MDA for scabies control in Queensland
Aboriginal communities in the early 1990s did not proceed due to administrative concerns
about medication safety and informed consent.[39] Instead the team conducted a MDA with
ivermectin in the Solomon Islands and showed ivermectin to be safe and effective with low sca-
bies prevalence persisting for at least 32 months.[31] The longer-term duration of benefit how-
ever, is unclear as there was no ongoing active surveillance. In Fiji, no significant difference was
found between MDAs with either ivermectin or benzyl benzoate after 24–28 days.[40]
To date, the use of ivermectin to treat scabies has not been associated with any serious
adverse effects nor were any observed in our study. However, it is recommended that ivermec-
tin not be administered to pregnant women or children who are younger than five years of age
or in those who weigh less than 15 kg. This recommendation is due to theoretical concerns
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regarding potential neurotoxicity and a lack of safety data. Although there have been no reports
of foetal problems when ivermectin has been administered in pregnancy to thousands of
women, caution is still recommended.[41] While the safety of ivermectin at the extremes of age
remains to be conclusively established, there is increasing evidence suggesting that the use of
ivermectin in children<5 years is safe.[26]
The high proportion of new entries to the cohort at the month 12 census (36%) coincided
with a large funeral that was attended by visitors from other communities who were camping
in tents in the house yards of relatives. At this time, many local residents were also displaced
from their homes into tents or other people’s homes as their houses were being refurbished or
demolished and rebuilt, as part of a government initiative to address housing shortages in
Aboriginal communities.[42] This change in population dynamics is considered highly mobile
by Australian mainstream standards, but does not reflect the stability reflected by the custom-
ary attachment of Aboriginal people to their home community and the regional area.[43]
The increased scabies prevalence at month 12 was notable in the 0–14 year age group and in
particular for those new participants to the cohort. Young children are particularly susceptible
to scabies infestations [2,4,44] and, as shown in this study, are more likely than adults to show
a change in prevalence. For population surveillance of scabies it has previously been recom-
mended that this is best achieved by monitoring the prevalence in young children,[4] a recom-
mendation that is further supported by this study.
At baseline there was concern about inter-observer variation in the diagnosis of scabies as
more females (n = 33) than males (n = 9) had been diagnosed with scabies. These concerns
were dispelled after reviewing the names of the researchers screening the children (for whom
the majority of scabies were diagnosed) and found that the female researchers, who at that time
had more experience in diagnosing scabies than the male researchers, had been conducting
most of the skin checks for male and female children. Thereafter we conducted regular reviews
of screening processes in the field and from photographs taken, to improve consistency in diag-
nosis and reduce inter observer variation.
It was also apparent to our community-based research team, that the relationship built over
the course of the team’s work meant that by month 12 it was relatively commonplace for
households to seek out the research team to assist in making their homes scabies free, and to
send family members who had not been present on the day the family were seen to the research
office for screening and treatment. We acknowledge that this may have introduced a screening
bias in the latter part of the study but the increased scabies prevalence at month 12 amongst
those who had been seen at baseline indicates that the increase in prevalence was not an arte-
fact of care-seeking behaviour.
The rise in scabies prevalence at month 12 coincided with: a cluster of cases epidemiologi-
cally-linked to an individual with presumptive crusted scabies, a high prevalence amongst new
entries to the cohort (an indicator of the impact of high population mobility), and an increased
prevalence amongst members of the baseline cohort who did not have a known exposure to the
suspected crusted scabies case (4% to 8%). This demonstrated how readily scabies prevalence
can increase. Control measures were able to be implemented promptly as the research team
had commenced the second house to house population census and MDA and were able to
coordinate the response with the local PHC services and community. Of note, was an outbreak
of APSGN [45] occurring at the same time in another large NT community that public health
personnel were responding to. Scabies prevalence in this community for children aged 1–17
years was 3% (n = 8) and 40.5% (n = 219) for purulent or crusted sores. Personal communica-
tion from the public health unit revealed there had been three cases of ARF and no cases of
APSGN reported in the region in the four months following the outbreak.
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Our study provides evidence that ivermectin based MDAs can have a role in reducing sca-
bies prevalence but also highlights that maintaining a reduction requires ongoing surveillance,
[4] diagnosis and chronic case management of individuals with crusted scabies,[18,34] and
ongoing engagement with community members that has a particular focus on households and
close contacts.[1] Due to the customary movements of Aboriginal people, regional approaches
to decrease re-introduction of scabies from neighbouring communities needs to be considered.
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